Loading news...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM.
Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
Cerity Partners LLC grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 942,270 shares of the biopharmaceutical company's stock after acquiring an additional 79,647 shares during the quarter. Cerity Partners
CX Institutional grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 165,742 shares of the biopharmaceutical company's stock after purchasing an additional 13,959 shares during the period.
Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Gateway Investment Advisers LLC raised its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 10.0% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 113,457 shares of the biopharmaceutical company's stock after purchasing an additional 10,284
Railway Pension Investments Ltd grew its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 3.7% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,139,600 shares of the biopharmaceutical company's stock after acquiring an additional 40,300
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference.
Generali Asset Management SPA SGR lowered its position in Bristol Myers Squibb Company (NYSE: BMY) by 16.5% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 242,287 shares of the biopharmaceutical company's stock after selling 47,870 shares during the quarter. Generali Asset Management
Cantor Fitzgerald Investment Advisors L.P. raised its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 6.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 289,715 shares of the biopharmaceutical company's stock after purchasing an additional 18,267 shares
Great dividend payers can support and raise their payouts through the years. VICI Properties is a leading REIT with a vast portfolio of experience-oriented properties.
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs.
Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device maker that's nearing Dividend King status.